Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study

BACKGROUND: This randomised phase II study compared the activity and safety of the combination docetaxel (D)/epirubicin (EPI) with the conventional treatment D/prednisone (P) in advanced castrate-resistant prostate cancer (CRPC) patients. MATERIALS AND METHODS: Patients were randomly assigned to D 3...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Petrioli, R, Pascucci, A, Conca, R, Chiriacò, G, Francini, E, Bargagli, G, Fiaschi, A I, Manganelli, A, De Rubertis, G, Barbanti, G, Ponchietti, R, Francini, G
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2011
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3049601/
https://ncbi.nlm.nih.gov/pubmed/21285986
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados